Clinical trials: Chronic Asthma
Study is Being Conducted in Healthy Volunteers
A Study to Assess How Much Drug Reaches the Blood When Given From Symbicort pMDI With Spacer Compared to That of Symbicort pMDI Without Spacer in Healthy Volunteers
This study will be conducted to establish the relative bioavailability of budesonide and formoterol delivered via Symbicort pressurized metered-dose inhaler (pMDI) with and without a spacer device.
- Trial name
- NCT02934607
- Testing
- Symbicort pMDI with spacer device, Symbicort pMDI without spacer device
- Where
- United Kingdom
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
An Investigation Of The Interaction Of GSK961081 With Inhaled Beta-Agonist And Anti-Muscarinic Drugs.
GSK961081 is a potent dual pharmacophore that demonstrates both antimuscarinic and beta-agonist pharmacology in preclinical studies, both pharmacologies being of long duration.
- Trial name
- NCT00674817
- Testing
- 400 microgrammes GSK961081, 1200 microgrammes GSK961081
- Where
- 4 sites in New Zealand, Thailand and 1 more
- Volunteers
- 45 people
- Sponsor
- Theravance Biopharma
Asthma
A Single Centre Study in Healthy Volunteers to Optimise the Rotacap Formulation and ROTAHALER Device for Delivery of Fluticasone Propionate/Salmeterol
The purpose of this study is to optimise the device and/or formulation of the Fluticasone propionate (FP)/salmeterol (SALM) unit dose powder inhaler (Rotahaler) to achieve drug delivery characteristics comparable to the…
- Trial name
- NCT01540708
- Testing
- SERETIDE Rotacaps, SERETIDE Diskus
- Where
- Australia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Breathlessness, COPD
Sentinel - Triaging Acute Breathlessness Using Multi-Modal Biomarkers
The Sentinel-001 study aims to identify a combination of biomarkers suitable for triage of breathlessness.
- Conditions
- Breathlessness, COPD, Asthma, Asthma Chronic
- Trial name
- NCT05304494
- Testing
- Biomarker tests for participant profiling
- Sponsor
- Sanome
Chronic Obstructive Pulmonary Disease
Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD8871 in Healthy Subjects
AZD8871 is a new chemical entity possessing long-acting effect in a single molecule which presents a novel treatment approach to chronic obstructive pulmonary disease [COPD] and potentially also asthma (in combination with an…
- Trial name
- NCT02814656
- Testing
- AZD8871
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Asthma, Chronic Obstructive Pulmonary Disease COPD
A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7594 Inhaled Formulation in Healthy Japanese Men
This is a randomized, single-blind, placebo-controlled, sequential-group study to assess the safety and tolerability as well as how the drug (AZD7594) affects the body (pharmacodynamics [PD]) and how the body affects the drug…
- Trial name
- NCT02645253
- Testing
- AZD7594 inhalation powder (200 μg), AZD7594 inhalation powder (400 μg), AZD7594 pressurized inhalation suspension (200 μg)
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Chronic Spontaneous Urticaria (CSU), Allergic Asthma
ROLL'YN-OMA: an Observational Study in Patients Treated by Omlyclo®, an Omalizumab Biosimilar
ROLL'YN-OMA is a real-world study in patients receiving standard biologic therapies who have been in control and/or remission of their disease for at least 3 months and whose physician has independently decided, within the…
- Trial name
- ROLL'YN-OMA (NCT07425639)
- Testing
- Omalizumab
- Where
- France
- Volunteers
- 225 people
- Sponsor
- Celltrion HealthCare France
COPD
Loop Band Validation Study
The main purpose of this study is to assess the accuracy of a non-invasive wearable technology in the form of a wristband.
- Trial name
- NCT03240926
- Testing
- Loop Band
- Where
- United States
- Volunteers
- 235 people, healthy volunteers welcome
- Sponsor
- Spry Health
Asthma-COPD Overlap Syndrome
A Non-interventional Study to Investigate the Current Situation of Asthma-COPD Overlap Syndrome in Patients Over Age 40 With Persistent Airflow Limitation in China
To investigate the distributions of the patients with ACOS, asthma and COPD over age 40 with chronic airflow limitation in China.
- Trial name
- NCT02600221
- Where
- 13 sites in China
- Volunteers
- 2,016 people
- Sponsor
- AstraZeneca
Nasal Polyps
Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps
This study will evaluate the efficacy and safety of depemokimab (GSK3511294) in participants with Chronic rhinosinusitis with nasal polyps (CRSwNP).
- Trial name
- ANCHOR-1 (NCT05274750)
- Testing
- Depemokimab (GSK3511294)
- Where
- 105 sites in United States, Argentina and 9 more
- Volunteers
- 276 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive, Asthma
Lung Deposition of the BDP/Formoterol Combination Administered Via the NEXT DPI in Healthy, Asthmatic and COPD Patients
The purpose of this study is to investigate the lung deposition and distribution pattern of Beclometasone and Formoterol using a gamma-scintigraphic technique after inhalation of a single dose of 99mTc-radiolabelled…
- Trial name
- NCT01176747
- Testing
- BDP/formoterol NEXT DPI
- Where
- Germany
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
Efficacy and Safety of Oral Roflumilast Taken With Low Dose Inhaled Corticosteroids in Patients With Asthma (12 to 70 y) (BY217/M2-013)
Bronchial asthma is among the world's most prevalent diseases. Roflumilast is a novel, orally active, selective enzyme inhibitor (phosphodiesterase 4 inhibitor), which has shown effectiveness in the treatment of asthma.
- Trial name
- NCT00163527
- Testing
- Roflumilast
- Where
- 24 sites in United States, Austria and 22 more
- Volunteers
- 2,054 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD), Asthma
Two-part Pharmacokinetic and Pharmacodynamic Study of LAS190792 in Patients With Asthma and COPD
The purpose of this study is to assess the safety and tolerability of single doses of LAS190792 administered by inhalation to patients with mild persistent asthma and moderate to severe chronic obstructive pulmonary disease…
- Trial name
- NCT02059434
- Testing
- LAS190792 Dose 1, LAS190792 Dose 2, LAS190792 Dose 3
- Where
- 2 sites in United Kingdom
- Volunteers
- 55 people
- Sponsor
- AstraZeneca
Pneumonia, Bronchiolitis
Diagnosing Respiratory Disease in Children Using Cough Sounds
The purpose of this prospective study is to evaluate the efficacy of the ResAppDx software application in diagnosis of pneumonia and other respiratory conditions (bronchiolitis, asthma/reactive airway disease, croup, upper or…
- Conditions
- Pneumonia, Bronchiolitis, Asthma, Croup
- Trial name
- SMARTCOUGH-C (NCT02973282)
- Testing
- Recording of Infants and Children's Cough Sounds
- Where
- 3 sites in United States
- Volunteers
- 1,245 people
- Sponsor
- ResApp Health Limited
Asthma, Chronic Obstructive Pulmonary Disease (COPD), Asthma Bronchiale
Investigation of Fixed Triple Inhaled Combination in Asthmatic Patients, in a Real-life Setting
The mainstay of asthma treatment are ICSs, mostly combined with LABA. In the past decade LAMA had been accepted as an add-on treatment for patients on GINA treatment Steps 4 and 5.
- Trial name
- STRENGTH (NCT06678191)
- Testing
- BDP/FF/G (Beclomethasone diprprionate, formoterol fumarate, glycopyrronium bromide) 172/5/9 μg
- Where
- 45 sites in Hungary
- Volunteers
- 800 people
- Sponsor
- Chiesi Hungary Ltd.
Chronic Asthma
The Safety and Effectiveness of MK0476 (Montelukast) in Patients With Chronic Asthma (0476-388)
This study will test the safety and effectiveness of a range of doses of MK0476 (montelukast) compared to placebo on improved lung function in patients with chronic asthma.
- Trial name
- NCT00739297
- Testing
- Comparator: montelukast
- Volunteers
- 68 people
- Sponsor
- Organon and Co
Asthma, Chronic Obstructive Pulmonary Disease
Evaluation of the Efficacy of Respicure® (Resveratrol / Quercetin) in the Management of Respiratory Conditions Including Asthma,COPD and Long COVID.
Interventional, Prospective, National, Multicentre, Randomised, Open-label, Controlled Clinical Study Comparing Two Parallel Groups, One Control Arm (Standard Treatment) Versus Intervention Arm (Standard Treatment + Study…
- Conditions
- Asthma, Chronic Obstructive Pulmonary Disease, Long COVID
- Trial name
- NCT05601180
- Testing
- Respicure®, Standard of care
- Where
- 8 sites in Algeria
- Volunteers
- 402 people
- Sponsor
- Beker Laboratories
Type 1 Diabetes, T1D
DASH-Obesity: Explainable AI for Family-Centric Personalized Weight Control in Adolescents and Young Adults With Obesity and Chronic Conditions
This prospective single-arm feasibility study evaluates the Adhera Caring Digital Program for Obesity (ACDP-O), a family-centered digital health intervention designed to support adolescents and young adults with…
- Conditions
- Type 1 Diabetes, T1D, Obesity & Overweight, Obesity Type 2 Diabetes Mellitus
- Trial name
- DASH-Obesity (NCT07638345)
- Testing
- Adhera Caring Digital Program-Obesity (ACDP-O)
- Where
- Spain
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Adhera Health, Inc.
Asthma, COPD
Prospective evAluatIon foR Inhalation Devices Study
ASTHMA: Asthma is a chronic inflammatory disorder of the airways in which many different types of cells, and various cellular components.
- Trial name
- PAIR (NCT01800994)
- Where
- 6 sites in Greece
- Volunteers
- 750 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Pulmonary Disease, Chronic Obstructive, Asthma
Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Patients With COPD.
The primary objective of this study is to determine the optimum dose(s) of BI 1744 CL inhalation solution delivered by the Respimat® inhaler for four weeks in patients with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00452400
- Testing
- BI 1744CL
- Where
- 42 sites in United States, Canada and 2 more
- Volunteers
- 409 people
- Sponsor
- Boehringer Ingelheim